An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

计划入组 105 人 · 首次发布于 2020 年 12 月 29 日

A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

计划入组 154 人 · 首次发布于 2020 年 1 月 28 日

Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy

计划入组 411 人 · 首次发布于 2017 年 12 月 14 日

TI-I-100

HOXB7 inhibitors (drug-resistant breast cancer)

focal adhesion kinase

Redpharm Drug

United States

Chain Drug Consortium

United States

Translational Drug Development

United States

Ovid Therapeutics Advances OV329 to Phase 2 Following Positive Safety Results in Drug-Resistant Epilepsy Program

Ovid Therapeutics' OV329 Shows 53% GABA Inhibition in Phase 1 Trial for Drug-Resistant Epilepsy

Rapport Therapeutics Prepares to Report Phase IIa Epilepsy Trial Results for RAP-219